J&J Stock Trades Near Highs With Talvey Data Bringing Pipeline Into View
Johnson & Johnson finished Friday at $240.87, up 1.07%. The stock outperformed other big healthcare names as the S&P 500 added 0.50% and the Dow Jones Industrial Average climbed 0.70%. The Dow, being price-weighted, gives more influence to higher-priced stocks like J&J. S&P Dow Jones Indices calls the Dow a gauge of 30 U.S. blue-chip companies. Johnson & Johnson on Saturday posted new Phase 3 MonumenTAL-3 data for its combination of Talvey and Darzalex Faspro, with or without pomalidomide, in patients with earlier-line relapsed or refractory multiple myeloma. According to the company, the combos slashed the risk of disease progression or death by as much as 72%, and cut risk of death by up to 53% compared to standard Darzalex Faspro, pomalidomide and dexamethasone treatment. Progression-free survival hit 81.3% at 24 months, while standard care stood at 51.2%. Overall survival was 89.2%, up from 79.1% for standard care.